Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025

Rhea-AI Summary

Iridex (Nasdaq: IRIX) will release third quarter 2025 financial results and provide a business update after market close on Tuesday, November 11, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.

Investors can join by dialing +1-888-596-4144 (US) or +1-646-968-2525 (international) and using Conference ID: 1504499. A live and recorded webcast will be posted on the company’s Investors > Event Calendar page at www.iridex.com.

News Market Reaction

+1.98%

1 alert

+1.98% News Effect

On the day this news was published, IRIX gained 1.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 from the US or +1-646-968-2525 internationally and providing Conference ID: 1504499 followed by pressing #. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

MicroPulse^® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2025 Iridex Corporation.  All rights reserved.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com

FAQ

When will Iridex (IRIX) report third quarter 2025 financial results?

Iridex will release Q3 2025 results after market close on November 11, 2025.

What time is the Iridex (IRIX) conference call for Q3 2025 results?

The conference call begins at 2:00 p.m. PT / 5:00 p.m. ET on November 11, 2025.

How can investors join the Iridex (IRIX) Q3 2025 earnings call?

Dial +1-888-596-4144 (US) or +1-646-968-2525 (international) and enter Conference ID: 1504499 followed by #.

Where will the Iridex (IRIX) earnings webcast be available?

A live and recorded webcast will be available on the company’s Investors > Event Calendar page at www.iridex.com.

Will Iridex (IRIX) provide a business update with its Q3 2025 results?

Yes; the company will release results and provide a business update after the close on November 11, 2025.

Is a replay of the Iridex (IRIX) Q3 2025 call available after the event?

Yes; a recorded webcast will be posted on the company’s Event Calendar page for later listening.